Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg Brentuximab
vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).